patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_128616 | REC_0016301 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13.4 | 50 | female | 0 | 12 | 4.8 | 2 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:36:01.683707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128901 | REC_0016302 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.2 | 73 | female | 0 | 13 | 6.4 | 9 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:36:01.684070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905465 | REC_0016303 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 18.1 | 66 | female | 0 | 7 | 6.5 | 0 | entrectinib 600 mg daily | 33.8 | false | MSI-H | 2026-03-15T05:36:01.685028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570097 | REC_0016304 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 11.2 | 68 | female | 0 | 18 | 4.5 | 6 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:36:01.685548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221401 | REC_0016305 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 6 | 69 | female | 0 | 18 | 7 | 2 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:36:01.685958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325340 | REC_0016306 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 15.1 | 61 | female | 1 | 16 | 5.7 | 1 | osimertinib 80 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:36:01.686357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453876 | REC_0016307 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 16.2 | 75 | female | 1 | 19 | 5.3 | 2 | entrectinib 600 mg daily | 12.8 | true | MSS | 2026-03-15T05:36:01.686764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635205 | REC_0016308 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 3.6 | 65 | male | 1 | 12 | 6.6 | 1 | pembrolizumab 200 mg q3w | 25.9 | false | MSS | 2026-03-15T05:36:01.687171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246110 | REC_0016309 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.3 | 68 | female | 1 | 18 | 6.4 | 2 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:36:01.687589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334131 | REC_0016310 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.5 | 54 | female | 0 | 34 | 3.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:36:01.688004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845828 | REC_0016311 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.4 | 64 | male | 0 | 22 | 4.7 | 4 | sotorasib 960 mg daily | 4.4 | false | MSI-H | 2026-03-15T05:36:01.688531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831194 | REC_0016312 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.7 | 74 | female | 2 | 60 | 3.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.4 | false | MSS | 2026-03-15T05:36:01.688948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105511 | REC_0016313 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.9 | 73 | female | 2 | 12 | 5.2 | 6 | sotorasib 960 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:36:01.689368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225806 | REC_0016314 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 2.8 | 69 | female | 1 | 50 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:36:01.689762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640625 | REC_0016315 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 17.8 | 61 | male | 1 | 14 | 3.4 | 9 | sotorasib 960 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:36:01.690384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332766 | REC_0016316 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 17.4 | 69 | female | 1 | 9 | 3.8 | 5 | sotorasib 960 mg daily | 16 | true | MSS | 2026-03-15T05:36:01.691069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152461 | REC_0016317 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 22.5 | 57 | female | 1 | 18 | 6.1 | 2 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:01.691588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771812 | REC_0016318 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 5.7 | 70 | female | 1 | 23 | 6.7 | 2 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:36:01.692011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930500 | REC_0016319 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 18.8 | 65 | male | 1 | 12 | 9.7 | 2 | osimertinib 80 mg daily | 16.8 | false | MSI-H | 2026-03-15T05:36:01.692482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177263 | REC_0016320 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.1 | 73 | female | 1 | 13 | 7 | 2 | alectinib 600 mg BID | 7.8 | true | MSI-H | 2026-03-15T05:36:01.692862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317071 | REC_0016321 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.9 | 70 | female | 0 | 11 | 4.3 | 6 | pembrolizumab 200 mg q3w | 8.1 | true | MSS | 2026-03-15T05:36:01.693217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944991 | REC_0016322 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.7 | 68 | female | 0 | 34 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.7 | false | MSS | 2026-03-15T05:36:01.693550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451221 | REC_0016323 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.7 | 56 | male | 0 | 67 | 7.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.2 | false | MSS | 2026-03-15T05:36:01.693911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825387 | REC_0016324 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.9 | 85 | female | 3 | 14 | 7.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 7.4 | true | MSS | 2026-03-15T05:36:01.694276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284803 | REC_0016325 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.8 | 71 | female | 1 | 22 | 7.1 | 1 | alectinib 600 mg BID | 17.4 | false | MSS | 2026-03-15T05:36:01.694616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874854 | REC_0016326 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 7.3 | 63 | female | 0 | 9 | 5 | 1 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:36:01.694957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755980 | REC_0016327 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 9.7 | 70 | female | 2 | 3 | 4.3 | 5 | sotorasib 960 mg daily | 14.7 | true | MSS | 2026-03-15T05:36:01.695269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703193 | REC_0016328 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 8 | 66 | female | 0 | 14 | 5 | 6 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:36:01.695583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113546 | REC_0016329 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 34 | 16.6 | 63 | female | 1 | 13 | 6.5 | 8 | pembrolizumab 200 mg q3w | 13.4 | true | MSI-H | 2026-03-15T05:36:01.696312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841799 | REC_0016330 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.9 | 55 | female | 1 | 18 | 6 | 3 | pembrolizumab 200 mg q3w | 11.6 | false | MSS | 2026-03-15T05:36:01.696855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848895 | REC_0016331 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 8.5 | 55 | male | 1 | 16 | 3.5 | 1 | alectinib 600 mg BID | 11.8 | false | MSS | 2026-03-15T05:36:01.697745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853992 | REC_0016332 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 15.4 | 64 | male | 1 | 15 | 7 | 4 | osimertinib 80 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:36:01.698371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115886 | REC_0016333 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13.4 | 55 | female | 1 | 12 | 4.5 | 6 | osimertinib 80 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:36:01.698863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785332 | REC_0016334 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 18.4 | 76 | male | 2 | 22 | 4.8 | 7 | entrectinib 600 mg daily | 7.4 | true | MSI-H | 2026-03-15T05:36:01.699278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610521 | REC_0016335 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.3 | 67 | female | 0 | 17 | 5.3 | 4 | alectinib 600 mg BID | 6.2 | false | MSI-H | 2026-03-15T05:36:01.699694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994028 | REC_0016336 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 8.6 | 77 | female | 1 | 5 | 7.4 | 0 | entrectinib 600 mg daily | 34.1 | false | MSS | 2026-03-15T05:36:01.700146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433126 | REC_0016337 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.6 | 77 | female | 1 | 22 | 6.6 | 5 | entrectinib 600 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:36:01.700529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811927 | REC_0016338 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 8.7 | 55 | male | 0 | 10 | 5.8 | 6 | pembrolizumab 200 mg q3w | 5.1 | true | MSS | 2026-03-15T05:36:01.700902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440409 | REC_0016339 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.6 | 55 | male | 1 | 11 | 5.1 | 7 | entrectinib 600 mg daily | 17 | false | MSS | 2026-03-15T05:36:01.701248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283395 | REC_0016340 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 10.4 | 81 | female | 3 | 24 | 7.8 | 0 | osimertinib 80 mg daily | 49 | false | MSI-H | 2026-03-15T05:36:01.701614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556593 | REC_0016341 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 13.4 | 77 | female | 2 | 17 | 5.2 | 1 | sotorasib 960 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:36:01.701937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563729 | REC_0016342 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.3 | 65 | female | 1 | 8 | 5.6 | 7 | alectinib 600 mg BID | 18.6 | true | MSI-H | 2026-03-15T05:36:01.702435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675236 | REC_0016343 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 8.7 | 62 | male | 1 | 11 | 5.3 | 2 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:01.702864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887225 | REC_0016344 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 12.4 | 65 | male | 1 | 12 | 4 | 6 | entrectinib 600 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:01.703252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710431 | REC_0016345 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 3.9 | 69 | female | 1 | 14 | 3.6 | 2 | sotorasib 960 mg daily | 19.3 | false | MSS | 2026-03-15T05:36:01.703610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473077 | REC_0016346 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 6.1 | 62 | female | 1 | 63 | 5.4 | 1 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:36:01.703958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788495 | REC_0016347 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.2 | 72 | male | 1 | 1 | 6.2 | 2 | alectinib 600 mg BID | 20.8 | true | MSS | 2026-03-15T05:36:01.704576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558822 | REC_0016348 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.9 | 63 | male | 1 | 4 | 7.3 | 4 | alectinib 600 mg BID | 10.9 | false | MSI-H | 2026-03-15T05:36:01.704977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816108 | REC_0016349 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 16.6 | 56 | male | 1 | 16 | 5.2 | 1 | osimertinib 80 mg daily | 19.5 | true | MSS | 2026-03-15T05:36:01.705327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869679 | REC_0016350 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.8 | 71 | female | 3 | 40 | 4.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.9 | true | MSS | 2026-03-15T05:36:01.706202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201926 | REC_0016351 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 13.7 | 69 | female | 1 | 16 | 4.4 | 3 | alectinib 600 mg BID | 30.7 | false | MSS | 2026-03-15T05:36:01.706703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494615 | REC_0016352 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.8 | 74 | female | 2 | 15 | 6.3 | 6 | pembrolizumab 200 mg q3w | 13.7 | true | MSS | 2026-03-15T05:36:01.707036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905071 | REC_0016353 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 2.5 | 52 | male | 0 | 16 | 6.3 | 5 | alectinib 600 mg BID | 11.2 | true | MSS | 2026-03-15T05:36:01.707389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562072 | REC_0016354 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 3.5 | 76 | female | 1 | 36 | 5.5 | 5 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:36:01.707758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940845 | REC_0016355 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 14.9 | 79 | female | 2 | 17 | 7.5 | 2 | entrectinib 600 mg daily | 20.6 | false | MSI-H | 2026-03-15T05:36:01.708611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989232 | REC_0016356 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 23 | 14.1 | 66 | female | 1 | 13 | 8.5 | 0 | alectinib 600 mg BID | 23.6 | true | MSS | 2026-03-15T05:36:01.709067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157719 | REC_0016357 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.3 | 57 | male | 0 | 12 | 5.8 | 0 | entrectinib 600 mg daily | 13.7 | false | MSS | 2026-03-15T05:36:01.709456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187708 | REC_0016358 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.4 | 73 | female | 1 | 72 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:36:01.709801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574909 | REC_0016359 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 8.9 | 64 | female | 1 | 15 | 7.8 | 10 | alectinib 600 mg BID | 11.9 | false | MSS | 2026-03-15T05:36:01.710215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985514 | REC_0016360 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 9.8 | 68 | female | 0 | 21 | 6 | 1 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:36:01.710563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654882 | REC_0016361 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 14.9 | 50 | male | 0 | 25 | 4.7 | 5 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:36:01.710918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124993 | REC_0016362 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 8.1 | 55 | female | 0 | 24 | 6 | 7 | sotorasib 960 mg daily | 15.7 | false | MSS | 2026-03-15T05:36:01.711272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463755 | REC_0016363 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 11.3 | 84 | female | 2 | 13 | 4.8 | 6 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:01.711606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299737 | REC_0016364 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 14.3 | 65 | female | 0 | 21 | 8.1 | 7 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:01.711962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488730 | REC_0016365 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 11.1 | 70 | female | 2 | 14 | 6.2 | 1 | osimertinib 80 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:36:01.712417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453623 | REC_0016366 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 14 | 3.7 | 78 | male | 1 | 7 | 4.2 | 2 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:36:01.712762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703290 | REC_0016367 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 6 | 67 | female | 0 | 13 | 4.7 | 1 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:36:01.713036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352790 | REC_0016368 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.6 | 48 | female | 0 | 21 | 5.5 | 4 | osimertinib 80 mg daily | 15.4 | true | MSS | 2026-03-15T05:36:01.713424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200234 | REC_0016369 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 6 | 65 | male | 1 | 5 | 5 | 1 | pembrolizumab 200 mg q3w | 4.8 | false | MSS | 2026-03-15T05:36:01.713709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281621 | REC_0016370 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.3 | 61 | female | 1 | 20 | 5.7 | 3 | osimertinib 80 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:36:01.714012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527440 | REC_0016371 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.3 | 54 | male | 0 | 31 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:36:01.714334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482083 | REC_0016372 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 17.3 | 50 | female | 0 | 31 | 5.7 | 7 | entrectinib 600 mg daily | 7.1 | false | MSS | 2026-03-15T05:36:01.714777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300246 | REC_0016373 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 12.9 | 61 | female | 0 | 34 | 5.2 | 1 | osimertinib 80 mg daily | 20.4 | false | MSS | 2026-03-15T05:36:01.715200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507273 | REC_0016374 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 17.6 | 66 | female | 0 | 19 | 3.9 | 2 | sotorasib 960 mg daily | 19.3 | false | MSI-H | 2026-03-15T05:36:01.715591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368613 | REC_0016375 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 10.3 | 66 | female | 1 | 25 | 5.4 | 1 | osimertinib 80 mg daily | 18.4 | false | MSS | 2026-03-15T05:36:01.716004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808424 | REC_0016376 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 17.6 | 67 | female | 0 | 22 | 6.8 | 2 | sotorasib 960 mg daily | 20 | true | MSS | 2026-03-15T05:36:01.716483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145621 | REC_0016377 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 21 | 7.7 | 70 | female | 1 | 19 | 6.7 | 0 | pembrolizumab 200 mg q3w | 35 | false | MSS | 2026-03-15T05:36:01.716889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813375 | REC_0016378 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 7.2 | 58 | male | 0 | 23 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.3 | true | MSS | 2026-03-15T05:36:01.717296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661054 | REC_0016379 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 15 | 68 | female | 0 | 22 | 4.5 | 2 | osimertinib 80 mg daily | 19.5 | true | MSS | 2026-03-15T05:36:01.717720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654110 | REC_0016380 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 9.9 | 58 | female | 0 | 58 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.2 | false | MSS | 2026-03-15T05:36:01.718075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342407 | REC_0016381 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.4 | 85 | male | 3 | 27 | 6.9 | 6 | alectinib 600 mg BID | 7.9 | false | MSI-H | 2026-03-15T05:36:01.718597+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123858 | REC_0016382 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 9.5 | 66 | female | 0 | 25 | 7.3 | 2 | alectinib 600 mg BID | 15.3 | false | MSS | 2026-03-15T05:36:01.719001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925432 | REC_0016383 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 7 | 78 | female | 1 | 9 | 4.4 | 4 | entrectinib 600 mg daily | 15.4 | true | MSS | 2026-03-15T05:36:01.719401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465790 | REC_0016384 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 10 | 52 | female | 0 | 14 | 4.9 | 7 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:36:01.719803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800878 | REC_0016385 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 11.9 | 72 | female | 0 | 7 | 4.8 | 0 | osimertinib 80 mg daily | 23.9 | false | MSS | 2026-03-15T05:36:01.720285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486357 | REC_0016386 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.2 | 55 | male | 1 | 22 | 5 | 5 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:36:01.720677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466517 | REC_0016387 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 12.4 | 58 | female | 0 | 8 | 5.1 | 7 | entrectinib 600 mg daily | 10 | false | MSS | 2026-03-15T05:36:01.721054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249911 | REC_0016388 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16.3 | 72 | female | 2 | 15 | 4.7 | 7 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:36:01.721503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397243 | REC_0016389 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 17 | 69 | male | 0 | 21 | 6.8 | 2 | osimertinib 80 mg daily | 21.2 | true | MSS | 2026-03-15T05:36:01.721935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697508 | REC_0016390 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 35 | 6.9 | 72 | female | 2 | 44 | 5.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.4 | false | MSS | 2026-03-15T05:36:01.722335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635746 | REC_0016391 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 10.7 | 72 | female | 1 | 12 | 6.8 | 7 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:36:01.722741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530109 | REC_0016392 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 11.1 | 70 | female | 2 | 25 | 5 | 2 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:01.723106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932540 | REC_0016393 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 19.3 | 75 | male | 2 | 3 | 8.4 | 6 | entrectinib 600 mg daily | 10.7 | false | MSS | 2026-03-15T05:36:01.723442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260955 | REC_0016394 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 14.5 | 58 | male | 0 | 18 | 4.5 | 2 | entrectinib 600 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:36:01.723960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803389 | REC_0016395 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 15.2 | 75 | female | 1 | 16 | 6.8 | 0 | osimertinib 80 mg daily | 33.1 | false | MSS | 2026-03-15T05:36:01.724431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173008 | REC_0016396 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 14.3 | 65 | female | 1 | 13 | 3.6 | 7 | osimertinib 80 mg daily | 13.7 | true | MSS | 2026-03-15T05:36:01.724881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880123 | REC_0016397 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 17.8 | 75 | female | 1 | 24 | 5 | 7 | entrectinib 600 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:36:01.725261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442214 | REC_0016398 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 10.8 | 61 | male | 0 | 15 | 7.8 | 2 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:36:01.725640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304140 | REC_0016399 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 12.9 | 61 | female | 1 | 8 | 6.2 | 1 | osimertinib 80 mg daily | 26.4 | false | MSI-H | 2026-03-15T05:36:01.726022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503397 | REC_0016400 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 11.3 | 57 | male | 0 | 10 | 4.8 | 2 | pembrolizumab 200 mg q3w | 20.1 | true | MSS | 2026-03-15T05:36:01.726440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.